AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03818685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Radiotherapy will be maintained in each Arm.
Study NCT03818685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Radiotherapy will be maintained in each Arm.
Study NCT03701815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness in Rehabilitation program
Description: The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
Study NCT00504660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.
Study NCT03755258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCK 100 mg + Placebo 200 mg
Description: GCK 100 mg + Placebo 200 mg, oral, 12 weeks
Study NCT03755258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCK 200 mg + Placebo 100 mg
Description: GCK 200 mg + Placebo 100 mg, oral, 12 weeks
Study NCT00504660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib (Celebrex)
Description: Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
Study NCT00504660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Arms 1,3 = 150 mg/m\^2 PO Daily On Day 4-8.
Study NCT00504660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Arms 2,3 = 100 mg/m\^2 PO on Day 4.
Study NCT03755258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCK 300 mg
Description: GCK 300 mg, oral, 12 weeks
Study NCT03755258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300mg
Description: Placebo 300mg, oral, 12 weeks
Study NCT01178047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rasagiline
Description: Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
Study NCT01178047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
Study NCT03217604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo
Study NCT03217604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06852231
Description: Treatment with PF-06852231
Study NCT00535496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
Study NCT01843621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEN vaccine F17
Description: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
Study NCT03606369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.
Study NCT03606369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
Study NCT00732030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric IOL (SN60T3)
Description: Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
Study NCT02887677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
Study NCT02887677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
Study NCT01853670 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemo + IGRT
Study NCT01853670 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemo + IGRT
Study NCT00071890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin 2
Description: Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
Study NCT00071890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: HAART from week 0 to week 24
Study NCT00071890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment interruption
Description: HAART is interrupted from week 24 in both arms
Study NCT01955252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months
Study NCT00330434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Trial Withdrawn 1
Description: Trial Withdrawn 1
Study NCT00330434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Trial Withdrawn 2
Description: Trial Withdrawn 2
Study NCT04412512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS approach
Description: video-assisted thoracic surgery approach
Study NCT04412512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracotomy approach
Study NCT02655120 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Drilling
Study NCT02655120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow +BMP7
Study NCT02650076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-1405
Study NCT00321620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Study NCT00321620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denosumab
Description: Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
Study NCT00905944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
Study NCT02490098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-day intervention with sensor-augmented pump therapy
Description: One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
Study NCT02490098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-day intervention with single-hormone closed-loop strategy
Description: One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
Study NCT02490098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-day intervention with dual-hormone closed-loop strategy
Description: One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
Study NCT02490098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study NCT00504660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-Thioguanine
Description: Arms 1,2,3 = 80 mg/m\^2 PO Every 6 Hours on Day 1-3.
Study NCT04330885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised abdominal exercises and stationary biking
Description: Explain pain to the patients in order to minimize fear of movement
Study NCT01011426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Description: 5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
Study NCT01011426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
Study NCT00706199 — intervention group
Intervention type: PROCEDURE
Intervention: Bone marrow aspiration
Description: Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
Study NCT03960307 — intervention group
Intervention type: OTHER
Intervention: Microcirculation and Glycocalyx assessment
Description: Non-invasive assessment of endothelial glycocalyx dimensions (PBR) and microcirculatory parameters (e.g. PPV, PVD, TVD, MFI)
Study NCT00953407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study NCT00953407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study NCT00953407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study NCT00953407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study NCT00953407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hilafilcon B contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study NCT00446628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behaviors reducing spread of influenza
Description: Non-pharmaceutical interventions for flu prevention
Study NCT02738736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium Reduction
Description: In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions
Study NCT04236505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) group based intervention
Description: 4 week ACT psychological intervention group based on Flaxman and McIntosh's ACT in the work place group format
Study NCT04236505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention
Description: 4 week Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention
Study NCT04236505 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list Control group
Description: this group are placed on a wait list for group treatment whilst the other experimental groups run. This group are offered the MBSR based mindfulness skills once the follow up data has been collected from the other two experimental groups
Study NCT02853838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged slow expiration+provoked coughing
Description: Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.~During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration.
Study NCT02853838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual chest wall vibration
Description: Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.~The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal.
Study NCT02853838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
Study NCT02853838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
Study NCT02088307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CardioLife
Description: Participants randomized to treatment arm will take dietary supplement as instructed.
Study NCT01597141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-aided Assertive Community Treatment
Description: The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
Study NCT01597141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard treatment
Description: In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention
Study NCT06258460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychotherapy training program intervention
Description: The intervention group will receive a two-day multimodal-based intensive educational intervention of CBT with 8 weeks follow-up (supervision based online teaching).
Study NCT06258460 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the wail-list control intervention
Description: The wail-list control group will receive a message encouraging them to complete all questionnaires from baseline to the last follow-up at 8 weeks.
Study NCT01639495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® SMARTTOUCH™ Catheter
Description: AF Ablation
Study NCT03290209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic D1 Lymphadenectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D1 Lymphadenectomy will be performed in the experimental group.
Study NCT03290209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic D2 Lymphadenectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D2 Lymphadenectomy will be performed in the comparator group.
Study NCT02552641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food effect
Study NCT02552641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Study NCT02552641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study NCT02552641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarythromycin
Study NCT01466634 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention with stent
Description: patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
Study NCT02634957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: absolute voice rest
Description: absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or whispering)
Study NCT02490098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
Study NCT02490098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring System Enlite sensor®, Medtronic
Description: Enlite sensor®, Medtronic
Study NCT02490098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump MiniMed® Paradigm® Veo™, Medtronic
Description: MiniMed® Paradigm® Veo™, Medtronic
Study NCT03650517 — intervention group
Intervention type: PROCEDURE
Intervention: Extracorporeal Anastomosis
Description: Anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
Study NCT03650517 — intervention group
Intervention type: PROCEDURE
Intervention: Intracorporeal Anastomosis
Description: Anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique
Study NCT03650517 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Procedure is performed using robotic instruments
Study NCT03650517 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Procedure is performed using standard laparoscopic instruments
Study NCT03823560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celegyn®
Description: Medical device Celegyn® presents itself as a cream.
Study NCT03823560 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: IP placebo presents itself as a cream.
Study NCT01824160 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Repair of RV-PA Conduit Disruption
Description: Repair of RV-PA Conduit Disruption
Study NCT06284148 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Screening for intimate partner violence
Description: confidential screening using exam computer
Study NCT06284148 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment and referral
Description: confidential assessment and referral of high-risk patients using decision-support templates
Study NCT02838433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological samples
Description: blood and tissue samples
Study NCT04568460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group Sessions
Description: Participants will undergo a multi-session group intervention over the course of six months.
Study NCT01617304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
Study NCT04040816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: SAP-001 or placebo treatment in a 4:1 randomization ratio
Study NCT00111527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized echo-guided CRT pacing
Description: Echo-TDI guided VV-delay optimization
Study NCT00111527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal RV pacing
Description: PM or ICD implant according to patient indication